2023-03-30 16:00Financial Performance - In 2022, the company achieved a revenue of RMB 12,629.58 million, representing a year-on-year growth of 4.69%[8] - The net profit attributable to shareholders was RMB 1,909.39 million, with a year-on-year increase of 7.53%[8] - The net cash flow from operating activities increased by 45.75% to CNY 2,772,671.30 thousand in 2022, compared to CNY 1,902,328.14 thousand in 2021[38] - The total assets as of December 31, 2022, were CNY 24,864,825.37 thousand, an increase of 11.14% from CNY 22,371,915.59 thousand in 2021[38] - The total liabilities increased by 23.17% to CNY 9,928,573.77 thousand in 2022, compared to CNY 8,060,890.80 thousand in 2021[38] - The basic earnings per share for 2022 was CNY 2.04, a 7.37% increase from CNY 1.90 in 2021[38] - The company's net assets attributable to shareholders increased by 6.71% to CNY 13,876,020.67 thousand in 2022, compared to CNY 13,003,763.63 thousand in 2021[38] - The company reported a decrease in the equity attributable to shareholders as a percentage of total assets to 55.81% in 2022, down from 58.13% in 2021[38] Dividends and Shareholder Returns - The company proposed a cash dividend of RMB 16.00 per 10 shares for the 2022 fiscal year, pending approval at the annual general meeting[8] - The board of directors has proposed a cash dividend of RMB 16.00 per 10 shares (including tax) for the 2022 fiscal year, pending approval at the annual general meeting[21] - The company will not issue bonus shares or conduct capital reserve transfers in the annual dividend plan[21] Research and Development - The company aims to enhance R&D efficiency and maintain its leading advantage in innovative drugs and complex formulations[13] - The company focuses on R&D innovation, particularly in unmet clinical needs, with a pipeline emphasizing innovative drugs and complex formulations[49] - The company has 26 ongoing key projects in R&D, with 5 in the production application stage and 3 in clinical trial approval stage[105] - The company has 86 ongoing research projects, with 1 in clinical stage and 15 technical improvement projects as of the end of 2022[108] - R&D expenses for the year totaled approximately RMB 1,401.27 million, a decrease of 8.01% from RMB 1,523.26 million in 2021, accounting for 11.10% of total revenue[103] Market and Product Development - The company is actively pursuing international collaboration opportunities to strengthen its market position and achieve sustainable development[11] - The company successfully launched the injection of Apalutamide in Indonesia, marking a significant milestone in international business expansion[57] - The company is focusing on innovative drug development in oncology, autoimmune diseases, and reproductive health, with several key projects progressing through clinical trials[62] - The company is advancing the development of a dual-valent vaccine against COVID-19 variants, with promising results in neutralizing efficacy against Omicron variants[60] - The company has completed the submission of registration materials for multiple products in overseas markets, with 19 product specifications approved in 11 countries/regions as of December 31, 2022[59] Corporate Social Responsibility - The company has committed approximately RMB 9.98 million to public welfare donations during the reporting period[12] - The company will continue to actively respond to national policy calls and strengthen social responsibility, focusing on providing precise assistance to chronic and rare disease populations[14] - The company aims to achieve carbon neutrality by 2055, emphasizing sustainable development and increasing investment in environmental protection[14] - The company expresses gratitude to shareholders, employees, and partners for their long-term support[14] Risk Management and Compliance - The company has analyzed potential risk factors and response strategies for future development in the management discussion and analysis section of the report[21] - The report includes forward-looking statements that may be affected by risks and uncertainties, and actual results may differ significantly[21] - The company emphasizes the importance of accurate and complete financial reporting, ensuring no misleading statements or omissions[20] Operational Efficiency - The marketing team enhanced professional and refined management, focusing on evidence-based and collaborative marketing strategies[11] - The company is enhancing its production and quality management systems to improve delivery capabilities and reduce operational costs, while promoting green production initiatives[58] - The company has established a comprehensive quality management system covering production, research, and sales processes, ensuring product safety and stability[78] Strategic Planning - The company anticipates that the Chinese pharmaceutical market will recover in 2023, with significant growth potential in the biopharmaceutical sector[13] - The company is focused on expanding overseas markets and advancing the consistency evaluation of related drugs to enhance competitiveness[195] - The company is prioritizing the development of high-value products and enhancing its market resilience through strategic planning and execution[183] Environmental Initiatives - The company is committed to energy conservation and emission reduction actions to meet its energy-saving and carbon reduction targets[14] - The company adheres to national environmental policies and regulations, increasing investment in environmental protection and aiming for carbon neutrality by 2055[199] Investment and Financing - The company reported a net increase in cash and cash equivalents of RMB 947.33 million, a significant improvement compared to a decrease of RMB 826.74 million in 2021[115] - The company received government subsidies amounting to RMB 183.35 million, contributing to 7.87% of total profit[120] - The total amount of funds raised by the company through a non-public offering was RMB 145,782.00 million, with RMB 142,030.04 million remaining after deducting issuance costs[165]